BioTuesdays

Tag - Maxim Group

RenovoRX
Markets

Maxim starts RenovoRx at buy; PT $15

Maxim Group launched coverage of RenovoRx (NASDAQ:RNXT) with a “buy” rating and price target of $15. The stock closed at $5.72 on Oct.5. RenovoRx is developing a therapeutic platform known as, RenovoTAMP (Trans-Arterial...

October 6, 2021
Clarus-Therapeutics
Markets

Maxim starts Clarus Therapeutics at buy; PT $13

Maxim Group initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with a “buy” rating and $13 price target. The stock closed at $5.61 on Sept. 28. Clarus is a commercial-stage company marketing Jatenzo, an oral...

September 29, 2021
180-Life-Sciences
Markets

Maxim starts 180 Life Sciences at buy; PT $11

Maxim Group initiated coverage of 180 Life Sciences (NASDAQ:ATNF) with a “buy” rating and $11 price target. The stock closed at $5.67 on Sept. 14. 180 Life Sciences is developing anti-inflammatory products with three...

September 15, 2021
Palisade Bio Logo
Markets

Maxim starts Palisade Bio at buy; PT $7

Maxim Group initiated coverage of Palisade Bio (NASDAQ:PALI) with a “buy” rating and price target of $7. The stock closed at $2.73 on Aug. 30. Palisade Bio is a clinical-stage company developing LB1148, an oral...

August 31, 2021
Immutep Logo
Markets

Maxim transfers coverage of Immutep at buy; PT $8

Maxim Group transferred primary coverage of Immutep (NASDAQ:IMMP) to analyst, Naureen Quibria, Ph.D., with a “buy” rating and $8 price target. The stock closed at $3.53 on July 15.  Immutep has a pipeline of...

July 16, 2021
Stealth BioTherapeutics Logo
Markets

Maxim starts Stealth BioTherapeutics at buy; PT $3

Maxim Group initiated coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and price target of $3. The stock closed at $1.56 on June 30. Stealth is developing compounds that target mitochondrial...

July 1, 2021
OSE Immunotherapeutics
Markets

Maxim starts OSE Immunotherapeutics at buy; PT $22

Maxim Group initiated coverage of OSE Immunotherapeutics (NXT PA:OSE) with a “buy” rating and $22 price target. The stock closed at $13.56 on June 22. Analyst Naureen Quibria, Ph.D., writes that French-based OSE has a...

June 23, 2021
Clene-Nanomedicine
Markets

Maxim starts Clene at buy; PT $18

Maxim Group launched coverage of Clene (NASDAQ:CLNN) with a “buy” rating and $18 price target. The stock closed at $8.95 on May 19. Clene is a clinical-stage company developing CNM-Au8, an oral, clean-surfaced faceted...

May 20, 2021